Advanced searches left 3/3

Type 2 Diabetes - U.S. Department of Veterans Affairs

Summarized by Plex Scholar
Last Updated: 09 June 2022

* If you want to update the article please login/register

Glucose Uptake by Skeletal Muscle within the Contexts of Type 2 Diabetes and Exercise: An Integrated Approach.

"Type 2 diabetes continues to have a negative effect on millions of people's lives. " Skeletal muscle is the key tissue for sustaining glucose homeostasis by glucose uptake by insulin-dependent and -independent methods. Skeletal muscle is also sensitive to exercise-meditated glucose transport, and as such, exercise is a keystone for glucose control in people with type 2 diabetes. A series of activities is needed to achieve a sleetal muscle glucose uptake. The glucose-rich blood must be transferred to the skeletal muscle first, first. "Lastly, intracellular metabolic pathways must be activated to maintain the diffusion gradient, which allows glucose transport into the cell. ".

Source link: https://doi.org/10.3390/nu14030647


Small molecule SWELL1 complex induction improves glycemic control and nonalcoholic fatty liver disease in murine Type 2 diabetes.

"Type 2 diabetes is also associated with insulin resistance, impaired pancreatic u03b-cell insulin secretion, and nonalcoholic fatty liver disease are all related to insulin resistance, impaired pancreatic u03b2-cell insulin secretion, and nonalcoholic fatty liver disease are associated with insulin resistance, impaired pancreatic u03b2-cell insulin secretion. " Insulin secretion and glycemic regulation are impaired by a tissue-specific SWELL1 ablation, which impairs insulin signaling in adipose, skeletal muscle, and endothelium, as well as impaired u03b2-cell insulin secretion and glucose control, as well as Tissue-specific SWELL1 ablation, which impairs insulin transport in adipose, skeletal muscle, and endothelium Here, we show that in murine and human diabetes, ICl,SWELL, and SWELL1 protein levels are reduced in adipose and u03b2-cells. These results show that SWELL1 channel modulators improve SWELL1-dependent systemic metabolism in Type 2 diabetes, providing a first-in-class therapeutic therapy for diabetes and nonalcoholic fatty liver disease in patients.

Source link: https://doi.org/10.1038/s41467-022-28435-0

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions